Yu-Guo Weng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu-Guo Weng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Stepanenko
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
1 shared publication - Axel Unbehaun
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany (D.S., H.H., A.U.).
1 shared publication Beate Jurmann
1 shared publication- Boris A. Nasseri
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
1 shared publication - Christof Stamm
Deutsches Herzzentrum Berlin, Cardiothoracic Surgery, Berlin, Germany
1 shared publication - Christoph Knosalla
Deutsches Herzzentrum der Charité, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353 Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partnersite Berlin, 10785 Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 18 March 2015
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 16 (4) , 327-8
Transcatheter aortic valve implantation for Chinese patients with bicuspid aortic valve.
- 18 March 2015
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 16 (4) , 327-8
Open AccessTranscatheter aortic valve implantation for Chinese patients with bicuspid aortic valve.
- Open Access
- 1 February 2012
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 3 (1) , 100-113
Prediction of True Circulatory Decompensation in Chronic Heart Failure for Optimal Timing of Mechanical Circulatory Support: Non-Invasive Arterial-Ventricular Coupling
Background: Prospective comparative studies to predict the risk of hemodynamic deterioration in patients referred for transplantation were performed on the basis of standard invasive and non-invasive data and new wave intensity (WI) parameters. Methods and results: Study Group 1 consisted of 151 consecutive outpatients (age 48.7 ± 12 years; 110 men) with end-stage dilative cardiomyopathy. Group 2, consisting of 11 consecutive patients (age 50 ± 11 years; 6 men) with sinus rhythm and “true” decompensation, was used to create “critical values” of WI. There were no demographic or somatic (weight and height) differences between the groups. The follow-up period of ambulatory patients was 31 ± 8 months. Non-invasive WI was studied in the common carotid artery. Complete invasive and non-invasive data were also recorded on the day of investigation. During follow-up 44 pts were lost; there were 15 cardiac deaths (10%), life-saving ventricular assist device implantation in 10 (6.6%) and transplantation in 19 (12.7%). For statistical purposes this group was named the “events” Group B (n = 44). A predisposing factor for events (death, “true” decompensation and “urgent” transplantation in ambulatory patients) was low first peak (“cut-off value” assessed in Group 2 < 4100 mmHg*s³) (OR 45.6, CI 14.5–143.3, p < 0.001). Less powerful predictors of the risk of deterioration were pulmonary capillary pressure (PCP), diastolic pulmonary artery pressure (PAP) and E/A mitral wave relation (p = 0.05). Conclusions: The new ventricular-arterial coupling parameter 1st peak of WI can potentially be used to distinguish patients at high risk for true deterioration and death. This parameter can be used to predict the need for assist device implantation.
- 1 February 2012
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 3 (1) , 100-113
Open AccessPrediction of True Circulatory Decompensation in Chronic Heart Failure for Optimal Timing of Mechanical Circulatory Support: Non-Invasive Arterial-Ventricular Coupling
Background: Prospective comparative studies to predict the risk of hemodynamic deterioration in patients referred for transplantation were performed on the basis of standard invasive and non-invasive data and new wave intensity (WI) parameters. Methods and results: Study Group 1 consisted of 151 consecutive outpatients (age 48.7 ± 12 years; 110 men) with end-stage dilative cardiomyopathy. Group 2, consisting of 11 consecutive patients (age 50 ± 11 years; 6 men) with sinus rhythm and “true” decompensation, was used to create “critical values” of WI. There were no demographic or somatic (weight and height) differences between the groups. The follow-up period of ambulatory patients was 31 ± 8 months. Non-invasive WI was studied in the common carotid artery. Complete invasive and non-invasive data were also recorded on the day of investigation. During follow-up 44 pts were lost; there were 15 cardiac deaths (10%), life-saving ventricular assist device implantation in 10 (6.6%) and transplantation in 19 (12.7%). For statistical purposes this group was named the “events” Group B (n = 44). A predisposing factor for events (death, “true” decompensation and “urgent” transplantation in ambulatory patients) was low first peak (“cut-off value” assessed in Group 2 < 4100 mmHg*s³) (OR 45.6, CI 14.5–143.3, p < 0.001). Less powerful predictors of the risk of deterioration were pulmonary capillary pressure (PCP), diastolic pulmonary artery pressure (PAP) and E/A mitral wave relation (p = 0.05). Conclusions: The new ventricular-arterial coupling parameter 1st peak of WI can potentially be used to distinguish patients at high risk for true deterioration and death. This parameter can be used to predict the need for assist device implantation.
- 17 June 2011
- Published by Georg Thieme Verlag KG in AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
- Vol. 46 (06) , 414-422
Herzinsuffizienz – Technische Möglichkeiten und Grenzen der mechanischen Kreislaufunterstützung
Mit Kunstherzsystemen (VAD) können der linke (LVAD), rechte (RVAD) bzw. beide Ventrikel des Herzens (BVAD) unterstützt werden. Traditional werden VAD-Systeme als Überbrückung bis zur Herztransplantation (BTT) implantiert; allerdings steigen in den letzten Jahren die Zahlen der permanenten Kreislaufunterstützung (DT) an. Eine Explantation eines VAD-Systems als „bridge to recovery“ (BTR) kommt nur für wenige Patienten in Fragen. Patientenselektion, prä- und intraoperatives Management sowie der Zeitpunkt der VAD-Implantation bestimmen den Erfolg dieser Therapie. Ventricular assist devices (VAD) to support the left (LVAD), the right (RVAD) or both ventricles (BVAD) have emerged as one standard of care for advanced heart failure patients. Initially used to bridge patients to transplantation (BTT) they are now more frequently implanted as permanent support (destination therapy, DT). Bridge to recovery (BTR) is a valid option for only a small number of patients. Although there are different devices available, patient selection, preoperative and intraoperative management, and the timing of VAD implantation are the elements critical to successful circulatory support.
- 17 June 2011
- Published by Georg Thieme Verlag KG in AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
- Vol. 46 (06) , 414-422
Herzinsuffizienz – Technische Möglichkeiten und Grenzen der mechanischen Kreislaufunterstützung
Mit Kunstherzsystemen (VAD) können der linke (LVAD), rechte (RVAD) bzw. beide Ventrikel des Herzens (BVAD) unterstützt werden. Traditional werden VAD-Systeme als Überbrückung bis zur Herztransplantation (BTT) implantiert; allerdings steigen in den letzten Jahren die Zahlen der permanenten Kreislaufunterstützung (DT) an. Eine Explantation eines VAD-Systems als „bridge to recovery“ (BTR) kommt nur für wenige Patienten in Fragen. Patientenselektion, prä- und intraoperatives Management sowie der Zeitpunkt der VAD-Implantation bestimmen den Erfolg dieser Therapie. Ventricular assist devices (VAD) to support the left (LVAD), the right (RVAD) or both ventricles (BVAD) have emerged as one standard of care for advanced heart failure patients. Initially used to bridge patients to transplantation (BTT) they are now more frequently implanted as permanent support (destination therapy, DT). Bridge to recovery (BTR) is a valid option for only a small number of patients. Although there are different devices available, patient selection, preoperative and intraoperative management, and the timing of VAD implantation are the elements critical to successful circulatory support.
- 31 August 2010
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 90 (2) , 580-587
Predictors for the Use of Left Ventricular Assist Devices in Infants With Anomalous Left Coronary Artery From the Pulmonary Artery
- 31 August 2010
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 90 (2) , 580-587
Predictors for the Use of Left Ventricular Assist Devices in Infants With Anomalous Left Coronary Artery From the Pulmonary Artery
- 1 March 2004
- Vol. 117 (3) , 401-7
Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy.
The purposes of this study were to confirm the changes in myocardial collagen level after left ventricular assist device (LVAD) support in dilated cardiomyopathy (DCM), find the relation between these changes and prognosis, and test a practical method to assess the level of myocardial collagen. Left ventricular samples were collected from DCM patients with different prognosis (transplanted group n = 8, weaning group n = 10) at the time when the LVADs were implanted and again during cardiac transplantation (n = 8). The level of neutral salt soluble collagen (NSC) and acid soluble collagen (ASC) was measured by Sircol collagen assay, and that of total collagen and insoluble collagen (ISC) by quantification of hydroxyproline (Hyp). Serum samples were collected from a portion of these patients (transplanted group, n = 6; weaning group n = 7) at the time the LVADs were implanted, 1 month after implantation and on explantation. Circulating concentration of carboxy-terminal propeptide of type I procollagen (P I CP), amino-terminal propeptide of type I procollagen (P I NP), amino-terminal propeptide of type III procollagen (P III NP) and type I collagen telopeptide (I CTP) were measured by the equilibrium type radioimmunoassay. Before LVAD implantation the level of NSC and ISC in the weaning group was higher but ASC in the transplanted group was lower than in the controls (P < 0.05). After LVAD support, the level of total collagen was higher, but ASC was also lower in the transplanted group than in the controls (P < 0.05). In comparison of the pre- and post-LVAD subgroups of the transplanted and weaning groups, all collagen fraction levels before LVAD implantation were lower in the transplanted group than in the weaning group (P < 0.05); but this difference disappeared after LVAD support. Comparison of the pre- and post-LVAD subgroups of the transplanted group showed increased level of NSC and total collagen after LVAD support. The changes of serum peptide concentration showed that P III NP increased constantly in the transplanted group, but P I CP and P I NP increased in the weaning group after LVAD implantation. The changes in myocardial collagen level as a sign of myocardial interstitial remodeling in DCM are not involved with total collagen but involved with collagen fractions, and they are related to prognosis. The changes of myocardial collagen content and serum procollagen peptide after LVAD support can be regarded as an expression of the reverse of maladaptive myocardial interstitial remodeling.
- 1 March 2004
- Vol. 117 (3) , 401-7
Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy.
The purposes of this study were to confirm the changes in myocardial collagen level after left ventricular assist device (LVAD) support in dilated cardiomyopathy (DCM), find the relation between these changes and prognosis, and test a practical method to assess the level of myocardial collagen. Left ventricular samples were collected from DCM patients with different prognosis (transplanted group n = 8, weaning group n = 10) at the time when the LVADs were implanted and again during cardiac transplantation (n = 8). The level of neutral salt soluble collagen (NSC) and acid soluble collagen (ASC) was measured by Sircol collagen assay, and that of total collagen and insoluble collagen (ISC) by quantification of hydroxyproline (Hyp). Serum samples were collected from a portion of these patients (transplanted group, n = 6; weaning group n = 7) at the time the LVADs were implanted, 1 month after implantation and on explantation. Circulating concentration of carboxy-terminal propeptide of type I procollagen (P I CP), amino-terminal propeptide of type I procollagen (P I NP), amino-terminal propeptide of type III procollagen (P III NP) and type I collagen telopeptide (I CTP) were measured by the equilibrium type radioimmunoassay. Before LVAD implantation the level of NSC and ISC in the weaning group was higher but ASC in the transplanted group was lower than in the controls (P < 0.05). After LVAD support, the level of total collagen was higher, but ASC was also lower in the transplanted group than in the controls (P < 0.05). In comparison of the pre- and post-LVAD subgroups of the transplanted and weaning groups, all collagen fraction levels before LVAD implantation were lower in the transplanted group than in the weaning group (P < 0.05); but this difference disappeared after LVAD support. Comparison of the pre- and post-LVAD subgroups of the transplanted group showed increased level of NSC and total collagen after LVAD support. The changes of serum peptide concentration showed that P III NP increased constantly in the transplanted group, but P I CP and P I NP increased in the weaning group after LVAD implantation. The changes in myocardial collagen level as a sign of myocardial interstitial remodeling in DCM are not involved with total collagen but involved with collagen fractions, and they are related to prognosis. The changes of myocardial collagen content and serum procollagen peptide after LVAD support can be regarded as an expression of the reverse of maladaptive myocardial interstitial remodeling.